Continuation Protocol for Obstructive Sleep Apnea (OSA)
← catalyst calendarSponsored by Apnimed (industry) · APMD — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Other
Enrollment
1,280estimated
Sites
99
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-03 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- OSA
Intervention
- Drug: Aroxybutynin and Atomoxetine — also filed as AD109
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AES) and Serious Adverse Events (SAEs)
measured through study completion, an average of 1 year
Number of Participants With Vital Signs Abnormalities
measured through study completion, an average of 1 year
Number of Participants With Concomitant Therapy (Medication or Devices)
measured through study completion, an average of 1 year
Permalink · APMD's whole pipeline · Catalyst calendar · Every registered study · What changed